Posted by Michael Wonder on 29 Nov 2018
Decision to remove funding restrictions for alendronate 70 mg products, decrease price, and award sole supply
30 November 2018 - PHARMAC is pleased to announce that the funding restrictions on alendronate 70 mg products will be removed from 1 February 2019. At the same time, the price and subsidy of these products will decrease.
The Fosamax and Fosamax Plus brands, supplied by MSD, will remain the only funded brands of alendronate 70 mg and alendronate 70 mg plus colecalciferol 5,600 iu, respectively.
These brands have been awarded sole supply until 30 June 2022, meaning that they will be the only funded brands until that date.
